Literature DB >> 23574971

Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score.

Johannes A N Dorresteijn1, Frank L J Visseren, Annemarie M J Wassink, Martijn J A Gondrie, Ewout W Steyerberg, Paul M Ridker, Nancy R Cook, Yolanda van der Graaf.   

Abstract

OBJECTIVES: To enable risk stratification of patients with various types of arterial disease by the development and validation of models for prediction of recurrent vascular event risk based on vascular risk factors, imaging or both.
DESIGN: Prospective cohort study.
SETTING: University Medical Centre. PATIENTS: 5788 patients referred with various clinical manifestations of arterial disease between January 1996 and February 2010. MAIN OUTCOME MEASURES: 788 recurrent vascular events (ie, myocardial infarction, stroke or vascular death) that were observed during 4.7 (IQR 2.3 to 7.7) years' follow-up.
RESULTS: Three Cox proportional hazards models for prediction of 10-year recurrent vascular event risk were developed based on age and sex in addition to clinical parameters (model A), carotid ultrasound findings (model B) or both (model C). Clinical parameters were medical history, current smoking, systolic blood pressure and laboratory biomarkers. In a separate part of the dataset, the concordance statistic of model A was 0.68 (95% CI 0.64 to 0.71), compared to 0.64 (0.61 to 0.68) for model B and 0.68 (0.65 to 0.72) for model C. Goodness-of-fit and calibration of model A were adequate, also in separate subgroups of patients having coronary, cerebrovascular, peripheral artery or aneurysmal disease. Model A predicted < 20% risk in 59% of patients, 20-30% risk in 19% and > 30% risk in 23%.
CONCLUSIONS: Patients at high risk for recurrent vascular events can be identified based on readily available clinical characteristics.

Entities:  

Mesh:

Year:  2013        PMID: 23574971     DOI: 10.1136/heartjnl-2013-303640

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  42 in total

1.  Comparison of Frequency of Atherosclerotic Cardiovascular Disease Events Among Primary and Secondary Prevention Subgroups of the Systolic Blood Pressure Intervention Trial.

Authors:  Timothy B Plante; Stephen P Juraschek; Neil A Zakai; Russell P Tracy; Mary Cushman
Journal:  Am J Cardiol       Date:  2019-09-06       Impact factor: 2.778

Review 2.  Smoking cessation for secondary prevention of cardiovascular disease.

Authors:  Angela Difeng Wu; Nicola Lindson; Jamie Hartmann-Boyce; Azizia Wahedi; Anisa Hajizadeh; Annika Theodoulou; Elizabeth T Thomas; Charlotte Lee; Paul Aveyard
Journal:  Cochrane Database Syst Rev       Date:  2022-08-08

3.  Bypass Grafting and Native Coronary Artery Disease Activity.

Authors:  Jacek Kwiecinski; Evangelos Tzolos; Alexander J Fletcher; Jennifer Nash; Mohammed N Meah; Sebastien Cadet; Philip D Adamson; Kajetan Grodecki; Nikhil Joshi; Michelle C Williams; Edwin J R van Beek; Chi Lai; Adriana A S Tavares; Mark G MacAskill; Damini Dey; Andrew H Baker; Jonathon Leipsic; Daniel S Berman; Stephanie L Sellers; David E Newby; Marc R Dweck; Piotr J Slomka
Journal:  JACC Cardiovasc Imaging       Date:  2022-02-16

4.  Coronary 18F-Sodium Fluoride Uptake Predicts Outcomes in Patients With Coronary Artery Disease.

Authors:  Jacek Kwiecinski; Evangelos Tzolos; Philip D Adamson; Sebastien Cadet; Alastair J Moss; Nikhil Joshi; Michelle C Williams; Edwin J R van Beek; Damini Dey; Daniel S Berman; David E Newby; Piotr J Slomka; Marc R Dweck
Journal:  J Am Coll Cardiol       Date:  2020-06-23       Impact factor: 24.094

5.  The incremental value of angiographic features for predicting recurrent cardiovascular events: Insights from the Duke Databank for Cardiovascular Disease.

Authors:  Michael G Nanna; Eric D Peterson; Karen Chiswell; Robert A Overton; Adam J Nelson; David F Kong; Ann Marie Navar
Journal:  Atherosclerosis       Date:  2021-02-08       Impact factor: 5.162

6.  Added value of cardiovascular calcifications for prediction of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease.

Authors:  Cilie C van 't Klooster; Yolanda van der Graaf; Hendrik M Nathoe; Michiel L Bots; Gert J de Borst; Frank L J Visseren; Tim Leiner
Journal:  Int J Cardiovasc Imaging       Date:  2021-02-12       Impact factor: 2.357

7.  Machine Learning with 18F-Sodium Fluoride PET and Quantitative Plaque Analysis on CT Angiography for the Future Risk of Myocardial Infarction.

Authors:  Jacek Kwiecinski; Evangelos Tzolos; Mohammed N Meah; Sebastien Cadet; Philip D Adamson; Kajetan Grodecki; Nikhil V Joshi; Alastair J Moss; Michelle C Williams; Edwin J R van Beek; Daniel S Berman; David E Newby; Damini Dey; Marc R Dweck; Piotr J Slomka
Journal:  J Nucl Med       Date:  2021-04-23       Impact factor: 11.082

8.  Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study.

Authors:  Alexis L Beatty; Ivy A Ku; Kirsten Bibbins-Domingo; Robert H Christenson; Christopher R DeFilippi; Peter Ganz; Joachim H Ix; Donald Lloyd-Jones; Torbjørn Omland; Marc S Sabatine; Nelson B Schiller; Michael G Shlipak; Hicham Skali; Madoka Takeuchi; Eric Vittinghoff; Mary A Whooley
Journal:  J Am Heart Assoc       Date:  2015-07-06       Impact factor: 5.501

9.  Coronary Artery Calcification as a Marker for Coronary Artery Stenosis: Comparing Kidney Failure to the General Population.

Authors:  Thijs T Jansz; Meike H Y Go; Nolan S Hartkamp; J Lauran Stöger; Csilla Celeng; Tim Leiner; Pim A de Jong; Frank J L Visseren; Marianne C Verhaar; Brigit C van Jaarsveld
Journal:  Kidney Med       Date:  2021-04-20

10.  NT-proBNP best predictor of cardiovascular events and cardiovascular mortality in secondary prevention in very old age: the Leiden 85-plus Study.

Authors:  Petra G van Peet; Yvonne M Drewes; Anton J M de Craen; Jacobijn Gussekloo; Wouter de Ruijter
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.